2011年版中国《肾细胞癌诊治指南》药物治疗原则解读

Interpretation of the principles of pharmacotherapy in Chinese Guideline for Renal Cell Carcinoma 2011

肾癌组织病理学分类复杂多样,但从临床药物治疗上分为透明细胞癌和非透明细胞癌两大类型。在我国目前对于转移性肾癌患者,药物治疗推荐分子靶向药物——索拉非尼为一线方案,其他分子靶向药物的推荐有待于中国的临床试验结果;细胞因子IFN-α或IL-2治疗对透明细胞癌类型肾癌也为一线推荐方案,而化疗可作为转移性非透明细胞类型肾癌的选择方案。伴有肾癌骨转移患者,推荐应用双膦酸盐药物,以减少骨相关事件的发生。局限性及局部浸润性肾癌患者术后尚无标准的可推荐的辅助治疗方案。

Renal cell carcinoma （RCC） has various kinds of histopathological classification. It can be classified as clear cell renal cell carcinoma and non-clear cell renal cell Carcinoma according to clinical drug therapy protocol. At present, sorafenib is recommended as the first-line molecular targeted therapy for patients with metastatic RCC in China. Other molecular target drugs are waiting for the results of clinical trials of Chinese. Cytokine therapy such as IFN-α or IL-2 is also the first-line recommended therapy for clear cell renal cell carcinoma, and chemotherapy as an option for patients with non-clear cell type histology. Bisphosphonates is recommended for patients with bone metastases which can reduce the incidence of bone-related events. Patients with localized or locally advanced RCC have no recommended post-operation adjuvant therapy.